^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-12 inhibitor

    Related drugs:
    11d
    Understanding the Role of H-Bonds in the Stability of Molecular Glue-Induced Ternary Complexes. (PubMed, J Chem Inf Model)
    We previously reported a significant correlation between protein-protein hydrogen bond robustness and the stability of the CRBN-CK1α complex induced by the antimyeloma drug lenalidomide. In this work, we demonstrate that this relationship is not unique for that system but rather represents a reproducible physicochemical phenomenon underlying the mechanism of action of chemically diverse MGs, including additional IMiDs and Fusicoccin A. Our results shed light on a vaguely understood phenomenon and pave the way for the development of new computational methods that enable the rational discovery of molecular glues.
    Journal
    |
    CRBN (Cereblon)
    |
    lenalidomide
    15d
    Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients. (PubMed, Am J Transl Res)
    Lenalidomide, bortezomib, and dexamethasone, demonstrate significant clinical efficacy in treating multiple myeloma.
    Clinical data • Journal
    |
    B2M (Beta-2-microglobulin)
    |
    lenalidomide • bortezomib • dexamethasone
    20d
    High leptin levels independent of body mass index are associated with inflammation and poorer treatment response in patients with diffuse large B-cell lymphoma. (PubMed, Biomed Pharmacother)
    Our results show that leptin levels are increased (independently of body mass index) in patients with DLBCL belonging to the R2-GDP-GOTEL phase II clinical trial, and these elevated levels are associated with a worse response to treatment and survival using lenalidomide as immunomodulator...Taken together, these data indicate that leptin could be a promising and predictive response biomarker of treatment efficacy in patients with lymphoma. Our findings on leptin in patients with R/R DLBCL could also arouse great interest given its potential applications as a target of treatment.
    Journal
    |
    CRP (C-reactive protein) • LEP (Leptin)
    |
    lenalidomide
    26d
    Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (clinicaltrials.gov)
    P1, N=30, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    CD4 (CD4 Molecule) • CD2 (CD2 Molecule)
    |
    lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
    1m
    Synthesis and Evaluation of AS1411-Lenalidomide-Targeted Degradation Chimera in Antitumor Therapy. (PubMed, Pharmaceuticals (Basel))
    This study provides compelling evidence demonstrating that C4 is a highly promising anticancer compound. It also provides important evidence for the development of novel nucleic acid aptamer-PROTAC conjugate drugs for more clinical applications.
    Journal
    |
    NCL (Nucleolin)
    |
    lenalidomide • QN-165
    1m
    Clinical and Biological Insights into Myelodysplastic Neoplasms Associated with Deletions of Chromosome 5q Region. (PubMed, Hematol Rep)
    These patients show a good prognosis and respond to treatment with lenalidomide, but some cases progress to acute myeloid leukemia...In other MDS patients, del(5q) is combined with other chromosomal abnormalities, giving rise to a condition of complex karyotype, associated with frequent TP53 mutations and with a poor prognosis. Two different molecular pathways seem to be responsible for the generation of MDS with isolated del(5q) or of MDS with del(5q) associated with a complex karyotype.
    Review • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(5q)
    |
    lenalidomide
    1m
    Immunoglobulin M Multiple Myeloma: Case Report of a Rare Variant of Multiple Myeloma with Diagnostic and Treatment Challenges. (PubMed, Ann Afr Med)
    The patient was treated with a bortezomib-based regimen including bortezomib, lenalidomide, and dexamethasone, along with supportive therapy including bisphosphonates and thromboprophylaxis. This case highlights the diagnostic complexity of IgM MM and emphasizes the importance of comprehensive evaluation, including bone marrow examination, advanced imaging, and detailed protein studies for accurate differentiation from other IgM-producing disorders. Early recognition and appropriate treatment with novel agents may improve outcomes in this rare myeloma variant.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • B2M (Beta-2-microglobulin)
    |
    lenalidomide • bortezomib • dexamethasone
    2ms
    NCI-2018-01614: Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2027 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide
    2ms
    Discovery of a dual-target CRBN-mediated degrader for IKZF1/3 and GSPT1 proteins. (PubMed, Bioorg Chem)
    Immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide degrade IKZF1/3 and are combined with other therapies to treat hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma. Molecular docking studies suggested that DIX-01 may form stable ternary complexes with CRBN-IKZF1 and CRBN-GSPT1, providing a structural basis for its dual-target degradation activity. Furthermore, DIX-01 significantly inhibited tumor growth in a zebrafish xenograft model transplanted with human acute myeloid leukemia cells (MV4-11), supporting its potential as a therapeutic agent for hematologic malignancies.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • GSPT1 (G1 To S Phase Transition 1)
    |
    lenalidomide • pomalidomide
    2ms
    RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. (PubMed, Cancer Biol Ther)
    Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    lenalidomide • bortezomib • cyclophosphamide
    2ms
    Lenalidomide for Adult Histiocyte Disorders (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2025 --> Feb 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    lenalidomide
    2ms
    Updates in low/intermediate-risk MDS. (PubMed, Hematology Am Soc Hematol Educ Program)
    New therapeutic options to reduce the red blood cell (RBC) transfusion burden have emerged since 2020 and include luspatercept and imetelstat. Erythropoiesis-stimulating agents and lenalidomide also address anemia and are generally recommended to start at the time of transfusion dependency, although emerging data suggest that an earlier start of these interventions might offer clinical benefits...Targeted therapy directed to the presence of an IDH1 mutation is U.S. Food and Drug Administration (FDA) approved for the rare IDH1 mutated MDS (<10% of the time) and consideration to use an IDH2 inhibitor for IDH2 mutated MDS (<5% of the time) is reasonable. Interestingly, IDH mutations seem to appear with increased frequency in older patients and in patients with underlying autoimmune/rheumatological disorders.1.
    Review • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH2 mutation
    |
    lenalidomide • Reblozyl (luspatercept-aamt) • Rytelo (imetelstat)